GSK shifts 2,200 posts for 'growth'

Instead of merely slashing reps to trim costs, GlaxoSmithKline is relocating the positions, said CEO Andrew Witty.

Last year, the company announced a 12% reduction in sales forces. In a third-quarter earnings presentation recapping the firm's return to top-line growth, Witty said his company's growth strategy involves shifting some of those US and European sales roles over to Asia-Pacific and emerging markets.

“Just over the last year or so,” the chief executive said in a web video, “we've reduced by around 2,200 the number of sales personnel in our established Western markets, and we've increased by around 2,200 the number of sales personnel in our emerging and Asia-Pacific markets—that's a good example of how we are reallocating resources to go for growth.”

The shifts are reflected in quarterly sales, up 25% in emerging markets and 19% in Japan. That's due to growth in pandemic flu vaccine and anti-viral Relenza, which is getting more government orders for swine flu, along with devices. Meanwhile, less than a third of total sales came from the “small white pills/Western markets” of the US and Europe, the company said.

In the last two months, the firm also received FDA approvals for cervical cancer vaccine Cervarix, oncology drug Votrient and Arzerra for oncology and rheumatoid arthritis.

As Witty sees it, simplifying the business model will remain a strong focus: “We continue to look for ways to drive greater efficiency and disinvest in areas which we believe no longer serve us well.”
You must be a registered member of MMM to post a comment.

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.